Skip to main content
Premium Trial:

Request an Annual Quote

Surge in Instrument Sales Helps Qiagen Post 21-Percent Revenue Growth in Q4

NEW YORK (GenomeWeb News) — Qiagen today said fourth-quarter revenue rose 21 percent as R&D spending increased 14 percent and net income widened 15 percent.
Total receipts for the three months ended Dec. 31, 2006, rose to $125.9 million from $104.3 million year over year. The increase was in part caused by a 47-percent increase in instruments sales, the company said.
Qiagen CEO Peer Schatz said 4 percent of the new revenue in the quarter came from the addition of 67 new products in 2006, including sample and assay technologies for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, applied testing, and molecular diagnostics.
R&D spending increased to $11 million from $9.7 million year over year.
The company said profit increased to $19.5 million $16.9 million in the year-ago period.
Qiagen said it had around $430 million in cash and equivalents and $52.8 million in short-term investments as of Dec. 31, 2006.
The company said it expects 2007 revenues to increase to between $518 and $535 million from the $466 million it generated in 2006.
Schatz said the company plans to expand its sample and assay portfolio and expects to make “a significant investment in clinical trials” for new diagnostic products.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.